Richard E. Gammans
President at Pamlico BioPharma, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Clayton Duncan | M | - |
Incara Pharmaceuticals Corp.
Pamlico BioPharma, Inc.
 Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK.
Otologic Pharmaceutics, Inc.
 Otologic Pharmaceutics, Inc. Pharmaceuticals: MajorHealth Technology Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK. | - |
| Robert A. Floyd | M | - |
Otologic Pharmaceutics, Inc.
Otologic Pharmaceutics, Inc. Pharmaceuticals: MajorHealth Technology Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK. | - |
| Richard Kopke | M | - |
Otologic Pharmaceutics, Inc.
Otologic Pharmaceutics, Inc. Pharmaceuticals: MajorHealth Technology Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK. | - |
| Mark Corrigan | M | 66 |
Pamlico BioPharma, Inc.
Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | - |
| Kelle Jones | F | - |
Pamlico BioPharma, Inc.
Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeff Himawan | M | 59 | 17 years | |
| Brian Anderson | M | 77 |
Indevus Pharmaceuticals, Inc.
 Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 5 years |
| Geoffrey O'Brien | M | 55 | 15 years | |
| Arlene Morris | F | 72 | 7 years | |
| Shintaro Asako | M | 50 | 6 years | |
| Michael Rogers | M | 64 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 10 years |
| John Prendergast | M | 70 | 7 years | |
| Stephen Prescott | M | - |
Incara Pharmaceuticals Corp.
| - |
| Marie Lalas | F | - | - | |
| Joji Suzuki | M | 56 | - | |
| Kenneth W. Locke | M | 67 | 8 years | |
| Alan Dunton | M | 70 | 5 years | |
| Chris Rallis | M | 70 |
Incara Pharmaceuticals Corp.
| - |
| Amit Kumar | M | 59 |
Incara Pharmaceuticals Corp.
| - |
| Thomas Forest Farb | M | 67 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 4 years |
| David B. Sharrock | M | 87 |
Incara Pharmaceuticals Corp.
| - |
| Daniel Vapnek | M | 85 | - | |
| Eugene McDonald | M | 91 |
Incara Pharmaceuticals Corp.
| - |
| Peter David Suzdak | M | 65 |
Incara Pharmaceuticals Corp.
| - |
| Edgar H. Schollmaier | M | 90 |
Incara Pharmaceuticals Corp.
| - |
| Michael E. Kalafer | M | 78 | 3 years | |
| Masatsune Okajima | M | 56 | 13 years | |
| Hideki Nagao | M | 67 | 6 years | |
| Noah Beerman | M | 62 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 12 years |
| Michael E. Lewis | M | 72 |
Incara Pharmaceuticals Corp.
| - |
| Joseph J. Krivulka | M | 73 |
Incara Pharmaceuticals Corp.
| - |
| Shayne C. Gad | M | - |
Incara Pharmaceuticals Corp.
| - |
| James D. Crapo | M | 81 |
Incara Pharmaceuticals Corp.
| - |
| Mark W. Lotz | M | 71 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 34 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard E. Gammans
- Personal Network
